The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …

Background While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L)
setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for …

Background Prognostic outcomes and safety following treatment with pembrolizumab in
patients with advanced urothelial carcinoma (UC) have not been fully elucidated in clinical …

Background Pembrolizumab is effective in a limited number of patients with advanced
urothelial carcinoma (UC). Therefore, we evaluated the prognostic value of clinical …

Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial
carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of …

Background Several studies have reported the incidence of immune-related adverse events
(irAEs) as a predictor of the efficacy of anti-programmed cell death protein 1 antibodies in …

Objectives To investigate the impact of the number of cycles and objective response to
chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated …

Background Few studies have investigated the safety and efficacy of anti-PD-(L) 1
antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge …

Background Limited data compare first-line carboplatin-based chemotherapy and immune
checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients …

Purpose: In an exploratory analysis, we investigated the association between programmed
death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell–inflamed gene expression …